- Policy
- Leukemia treatment ‘Venclexta’ to be reimbursed
- by Lee, Hye-Kyung May 31, 2021 06:02am
- ‘Venclexta (venetoclax)’ in combination with ‘MabThera (rituximab)’ will be reimbursed as second-line treatment for patients with chronic lymphocytic leukemia. The Health Insurance Review and Assessment Service (HIRA) has been conducting an opinion inquiry on its proposed revision of the ‘Notices required according to drugs prescrib
- Policy
- It's necessary to go through the social consensus
- by Lee, Jeong-Hwan May 28, 2021 06:08am
- It is argued that conflicts between doctors and pharmacists were not be resolved despite government intervention in order to legislate for the activation of the generic substitution, and that they should go through the social consensus process that took place at the time of the separation of prescribing and dispensing. They say that citiz
- Policy
- One-time ￦2 billion therapy Zolgensma to be soon approved
- by Lee, Tak-Sun May 27, 2021 05:56am
- Zolgensma (onasemnogene abeparvovec-xioi), a new gene therapy drug that attracted attention due to its high price of nearly 2 billion won per single shot, is soon to be approved in Korea. As a spinal muscular atrophy gene therapy, Zolgensma is also called a ‘one-shot treatment’ as only a single dose is required during a patient’s lifet
- Policy
- Combination vaccine Priorix-tetra by GSK has been revoked
- by Lee, Tak-Sun May 27, 2021 05:55am
- The final license will be revoked because GSK's licensed combination vaccine "Priorix-tetra" did not submit the review data in November 2013. The vaccine is the first MMRV vaccine in Korea to have chickenpox prevention added to existing measles, rubella, and infectious mastitis. However it seems that GSK has not been able to actively respo
- Policy
- 55,000 doses of Mordena vaccines will be released in a week
- by Kim, Jung-Ju May 26, 2021 06:05am
- Moderna's 55,000 mRNA-like COVID-19 vaccines will arrive in Korea next Monday, or the 31st. The COVID-19 vaccine, developed by foreign pharmaceutical companies in Korea, is the third since AstraZeneca and Pfizer, and has been rapidly introduced since the signing of an MOU between health authorities and companies. The MOHW announced on t
- Policy
- Moderna COVID-19 vaccine is finally licensed
- by Lee, Tak-Sun May 25, 2021 06:03am
- Moderna COVID-19 Vaccine has obtained a final item license in Korea. The MFDS announced on the 21st that GC Pharma has decided to permit imported items on the condition that it submits a final report on clinical trials for Moderna COVID-19 Vaccine, which it applied for permission for imported items on April 12. Moderna COVID-19 Vaccine
- Policy
- National Assembly is paying attention to news of AZ-Pfizer's
- by Lee, Jeong-Hwan May 24, 2021 05:50am
- Overseas studies have shown that the second shot of the Pfizer-Biontech vaccine after the first shot of the COVID-19 vaccine developed by AstraZeneca (AZ) and Oxford University is effective and safe. The National Assembly also seems to be interested in responding to domestic quarantine authorities regarding cross-vaccination. Based on oversea
- Policy
- 438,000 doses of Pfizer Vaccines are received on the 19th
- by Lee, Jeong-Hwan May 24, 2021 05:50am
- On the 19th, an additional 438,000 doses of COVID-19 vaccine, which South Korea directly contracted with Pfizer, will arrive in South Korea. It is part of the 7 million units that are scheduled to be supplied in the first half of the year, which are received in small quantities every week. Lee Sang-won, head of the Central Disease Control
- Policy
- Antibiotics & Viagra were detected in the Han River
- by Lee, Jeong-Hwan May 21, 2021 05:27am
- As Viagra (Sildenafil) was detected in the Han River, the drinking water source, for the first time following the residual antibiotics in the soil and rivers, related government ministries are criticized for not only identifying the situation but also preparing measures to prevent recurrence. It was focused on identifying whether waste med
- Policy
- Samsung & Pfizer compete in Avastin biosimilar market
- by Lee, Tak-Sun May 21, 2021 05:26am
- Samsung Bioepis and Pfizer will compete in the domestic market for anti-cancer drug Avastin (Bevacizumab, Roche Korea). There will be a rare competition between domestic companies and global companies over generics. The MFDS approved Jairabeve of Pfizer Korea on the 18th. Jairabeve (Bevacizumab) is biosimilar for Avastin in Roche, Korea.
